Regulations.gov document
Demonstrating Bioequivalence for Soluble Powder Oral Dosage Form Products and Type A…
Notice · FDA-2019-D-3764 · posted May 21, 2021
Key facts
| Document ID | FDA-2019-D-3764-0003 |
|---|---|
| Title | Demonstrating Bioequivalence for Soluble Powder Oral Dosage Form Products and Type A Medicated Articles Containing Active Pharmaceutical Ingredients Considered To Be Soluble in Aqueous Media; Guidance for Industry; Availability |
| Document type | Notice |
| Subtype | Notice of Availability |
| Agency | FDA |
| Docket | FDA-2019-D-3764 |
| Posted | May 21, 2021 |
| Federal Register citation | 86 FR 27633 |
| FR document number | 2021-10756 |
| Comment period opens | May 21, 2021 |
| Effective date | May 21, 2021 |
At a glance
- 1–9 Pages
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: